Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study

• DOI: 10.1093/jac/dkx042
• Publication Date: 2017-01-30T13:23:51Z
• Authors: L. Assoumou; C. Charpentier; P. Recordon-Pinson; M. Grudé; C. Pallier; L. Morand-Joubert; S. Fafi-Kremer; A. Krivine; B. Montes; V. Ferré; M. Bouvier-Alias; J.-C. Plantier; J. Izopet; M.-A. Trabaud; S. Yerly; J. Dufayard; C. Alloui; L. Courdavault; H. Le Guillou-Gui...; A. Maillard; C. Amiel; A. Vabret; C. Roussel; S. Vallet; J. Guinard; A. Mirand; A. Beby-Defaux; F. Barin; A. Allardet-Servent; R. Ait-Namane; M. Wirden; C. Delaugerre; V. Calvez; M.-L. Chaix; D. Descamps; S. Reigadas
• Keywords: HIV drug resistance; Integrase inhibitor; Protease inhibitor (pharmacology)

Background: Surveillance of HIV-1 resistance in treated patients with a detectable viral load (VL) is important to monitor, order assess the risk spread resistant viruses and determine proportion who need new antiretroviral drugs minimal cross-resistance. Methods: The protease reverse transcriptase (RT) integrase genes were sequenced plasma samples from 782 consecutive on failing regimens, seen 37 specialized centres 2014. genotyping results interpreted using ANRS v24 algorithm. Prevalence rates compared those obtained during similar survey conducted 2009. Results: RT sequences 566 patients, sequence 382 patients. Sequencing was successful 60%, 78%, 78% 87% VLs 51–200, 201–500, 501–1000 >1000 copies/mL, respectively. Resistance at least one drug detected 56.3% samples. Respectively, 3.9%, 8.7%, 1.5% 3.4% harboured that any NRTI, NNRTI, PI inhibitor (INI). lower 2014 than 48.5% VL between 51 200 copies/mL. Conclusion: In France 2014, 90.0% AIDS care receiving 12.0% them had >50 Therefore, this study suggests 6.7% might transmit strains. testing may be warranted all > 50